USC Researchers Adopted New Nanovial Cell Tech

A $2.5 million award supports a study at USC utilizing Partillion Bioscience technology to improve CAR T-cell therapies.

Updated on Oct. 14, 2026 in Biotech

Isometric editorial illustration of a clinical nanovial analysis instrument, representing medical research technology. — The California Institute for Regenerative Medicine awarded $2.5 million to USC researchers using nanovial technology to enhance CAR T-cell therapy potency. AI Illustration. Upload story photo >

Live Poll

Should government agencies prioritize funding for research into experimental cell-based cancer therapies?

The California Institute for Regenerative Medicine has awarded $2.5 million to a USC-led project focusing on CAR T-cell potency. The team will use Partillion Bioscience Nanovial technology to analyze immune and tumor cell interactions.

Why it matters

Standard clinical measurements often fail to capture the functional differences between individual cells. This research aims to identify why certain CAR T-cell interactions succeed while others fail, potentially enabling the development of more durable therapies.

The study utilizes Nanovials to connect immune and tumor cell interactions with gene expression changes, combining this with high-dimensional flow cytometry. The project seeks to build a comprehensive CAR T-cell atlas to monitor cellular potency and persistence.

The players

Mohamed Abou-el-Enein

He is the lead researcher at the University of Southern California directing this CAR T-cell study.

Partillion Bioscience

This company provides the specialized Nanovial technology used to analyze single-cell functional interactions.

California Institute for Regenerative Medicine

This agency oversees the distribution of state-funded grants to accelerate stem cell and regenerative medicine research.

The details

Led by Mohamed Abou-el-Enein, researchers at the USC Keck School of Medicine are using Nanovial-based Cell-Cell-seq to study samples. These patient-derived materials are being collected from the Community Care Center of Excellence at Loma Linda University.

October 14, 2026: Partillion Bioscience announced its participation in the USC-led research project.

The Tech Race

This project represents a push to modernize cellular analysis by moving beyond traditional population-level measurements. It follows the broader industry trajectory of integrating high-throughput single-cell sequencing to gain precise control over advanced immunotherapy production.

For patients undergoing immunotherapy, this research aims to eventually lead to more consistent and effective cell-based treatments. The integration of high-resolution sequencing may help clinicians better predict which therapies will offer the most durable results.

The takeaway

Advancing CAR T-cell research requires moving beyond average population data to understand the unique functional behavior of individual cells. This project demonstrates how specialized microfluidics and sequencing tools are becoming essential for the next generation of personalized cancer medicine.